Lite Strategy, Inc. Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized
Lite Strategy, Inc. (LITS) reported Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized of $0 for the 12-month period ending 2024-06-30, per its 10-K filed 2025-09-26.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityChangeInTimeframePerformanceObligationSatisfiedRevenueRecognized · last filed 2025-09-26
- Lite Strategy, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2024-03-31 was $0.00.
- Lite Strategy, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for the quarter ending 2023-09-30 was $0.00.
- Lite Strategy, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2024 was $0.00.
- Lite Strategy, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2023 was -$16.57M.
- Lite Strategy, Inc. contract with customer, liability, change in timeframe, performance obligation satisfied, revenue recognized for fiscal 2022 was $0.00.
| Period end | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 3 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 6 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 9 month | Contract with Customer, Liability, Change in Timeframe, Performance Obligation Satisfied, Revenue Recognized 12 month |
|---|---|---|---|---|
| 2024-06-30 | $0.00 10-K · filed 2025-09-26 | |||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-09 | |||
| 2023-12-31 | $0.00 10-Q · filed 2024-02-13 | |||
| 2023-09-30 | $0.00 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | -$16.57M 10-K · filed 2024-09-19 | |||
| 2023-03-31 | -$16.57M 10-Q · filed 2023-05-11 | |||
| 2022-12-31 | -$16.57M 10-Q · filed 2023-02-09 | |||
| 2022-06-30 | $0.00 10-K · filed 2023-09-26 | |||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-Q · filed 2023-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |